Cormedix Inc.
A biopharmaceutical company that makes Defencath, a catheter lock solution used by kidney-dialysis patients to prevent bloodstream infections and blood clotting. Founded in 2006 by Antony P. Pfaffle, the firm began life as Picton Holding Company and was renamed CorMedix a few months later. The name blends the Latin "cor" (heart) with "medix," a nod to the medical conditions it addresses.
Granted 1.00M · Bought 63.3K · Sold 80.0K
Granted 410.5K · Sold 194.0K
Granted 308.8K · Sold 50.0K
Granted 55.5K · Bought 46.0K
Granted 105.5K · Sold 40.0K
Granted 142.5K
Granted 133.2K
Granted 112.5K · Bought 2.5K
Granted 112.5K · Bought 3.0K
Granted 85.5K · Bought 9.0K · Sold 30.0K
Granted 162.5K · Sold 147.0K
Granted 68.8K
Granted 55.5K · Bought 10.0K
Bought 10.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Todisco JosephChief Executive Officer, Director · 26 transactions | — | 774.7K | 1.00M | 63.3K | 80.0K |
| Hurlburt ElizabethChief Operating Officer · 20 transactions | +3381.7% | 278.5K | 410.5K | — | 194.0K |
| Zelnick Kaufman BethChief Legal Officer · 14 transactions | — | 269.1K | 308.8K | — | 50.0K |
| Kaplan MyronDirector · 10 transactions | — | 261.5K | 55.5K | 46.0K | — |
| Lefkowitz Steven WDirector · 6 transactions | +76.4% | 158.1K | 105.5K | — | 40.0K |
| Blum SusanChief Financial Officer · 3 transactions | — | 142.5K | 142.5K | — | — |
| Seckler Michael DavidChief Commercial Officer · 1 transaction | — | 133.2K | 133.2K | — | — |
| Mistry ErinEVP, Chief Commercial Officer · 7 transactions | — | 101.0Kas of Jan 2025 | 112.5K | 2.5K | — |
| David Matthew TChief Financial Officer · 8 transactions | +8184.3% | 95.3Kas of Jan 2025 | 112.5K | 3.0K | — |
| Dunton Alan WDirector · 9 transactions | +1031.2% | 70.7K | 85.5K | 9.0K | 30.0K |
| Dillione JanetDirector · 16 transactions | +28.9% | 68.9K | 162.5K | — | 147.0K |
| Duncan Gregory ScottDirector · 3 transactions | — | 68.8K | 68.8K | — | — |
| Stewart Robert ADirector · 3 transactions | — | 66.5K | 55.5K | 10.0K | — |
| Costa Paulo FDirector · 1 transaction | — | 10.0Kas of May 2023 | — | 10.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -397.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.